Last updated on September 2018

Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients


Brief description of study

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.

Clinical Study Identifier: NCT03078582

Contact Investigators or Research Sites near you

Start Over

Investigative Site
North Gosford, New South Wales, Australia

Investigative Site
Parkville, Australia

Investigative Site
Copenhagen, Denmark

Investigative Site
Helsinki, Finland

Investigative Site
Essen, Germany

Investigative Site
Ulm, Germany

Investigative Site
Budapest, Hungary

Investigative Site
Christchurch, New Zealand

Investigative Site
Hamilton, New Zealand

Investigative Site
Leeds, United Kingdom

Investigative Site
London, United Kingdom

Investigative Site
Toronto, ON Canada